On 10 June 2016, the merger of Skyepharma PLC and Vectura Group plc completed and the combined group will be the Vectura Group. Skyepharma’s website is no longer being updated. Please refer to www.vectura.com.
Skyepharma was established in 1996, by the acquisition of Jago Pharma AG, which had been a drug delivery specialist since 1983. Today Skyepharma is a leading expert drug delivery company with a proven range of oral and inhalation product development capabilities and technologies.
Our research and development laboratories are located in Muttenz, near Basel in Switzerland, where our experienced teams of scientists formulate and develop innovative inhalation and oral modified release pharmaceutical products. Our proven capabilities in solving complex formulation issues, combined with pre-clinical, clinical and regulatory expertise and the application of proprietary technologies has resulted in 14 currently approved products that are sold in over 80 countries. The products are marketed throughout the world by both large pharmaceutical companies and specialty pharmaceutical companies.
Skyepharma enhances its product pipeline by adding innovative products arising from its own research as well as work done in collaboration with partners. The Group's formulation and development capabilities and enabling technologies in the areas of inhaled and oral controlled drug delivery are available to other pharmaceutical companies on a partnered development and licensing basis.
Skyepharma's headquarters are in London, and its shares are traded on the London Stock Exchange under the symbol SKP.